États-Unis · Plateformes & données · Morningstar

Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

Publié par Morningstar · États-Unis il y a 12 h

Supports serial testing in the surveillance setting for patients with early-stage HCC Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

À lire aussi

Needham & Company LLC Issues Pessimistic Forecast for Cipher Mining (NASDAQ:CIFR) Stock Price

Revvity rises on full-year guidance boost

Warren Buffett Has 1 Simple Rule for Investing During Bear Markets. History Says He's Right.

Stock market after midterm elections: What S&P 500 history shows

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

5 questions to ask if your boss offers you a buyout, as Microsoft did with 60,000 employees

Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

Partager

À lire aussi

Needham & Company LLC Issues Pessimistic Forecast for Cipher Mining (NASDAQ:CIFR) Stock Price

Revvity rises on full-year guidance boost

Warren Buffett Has 1 Simple Rule for Investing During Bear Markets. History Says He's Right.

Stock market after midterm elections: What S&P 500 history shows

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

5 questions to ask if your boss offers you a buyout, as Microsoft did with 60,000 employees